Adversarial Injection · Enzalutamide (Xtandi; MDV3100; NDA 203415; CAS 915087-33-1; MW ~464.4 g/mol; diarylthiohydantoin [4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]-2-fluoro-N-methylbenzamide] scaffold [FORTY-FIFTH MECHANISM CLASS in Glyphward 602-attack portfolio — FIRST NEXT-GENERATION ANDROGEN RECEPTOR (AR) SIGNALING INHIBITOR EVER FDA APPROVED: prior to NDA 203415 (August 31 2012), all approved AR antagonists were FIRST-GENERATION with partial agonism (bicalutamide CAS 90357-06-5 approved 1995: Kd ~8.5 nM AR LBD, partial agonist at high AR expression → T877A/W741C AR mutations in castration-resistant disease cause bicalutamide to act as FULL AGONIST driving mCRPC progression; flutamide CAS 13311-84-7 approved 1989; nilutamide CAS 63612-26-0 approved 1996; all three first-generation agents have partial agonist activity that drives resistance); enzalutamide (MDV3100) is the FIRST AR ANTAGONIST WITH ZERO AGONIST ACTIVITY AT ANY DOSE: (1) AR LBD BINDING: Kd ~0.9 nM — 8-9× higher affinity than bicalutamide; diarylthiohydantoin occupies AF-2 helix-12 and BF-3 surface simultaneously; induces AR LBD into antagonist conformation; (2) NUCLEAR TRANSLOCATION BLOCK: enzalutamide-bound AR cannot recruit importin-α/β nuclear transport machinery → AR remains sequestered in cytoplasm with HSP90/HSP70 chaperones; even in conditions of AR overexpression (F876L resistance mutation drives partial agonism, but that mutation = distinct resistance pattern); (3) AR-DNA BINDING BLOCK: if trace nuclear AR present, enzalutamide prevents ARE (androgen response element) DNA binding; (4) COACTIVATOR RECRUITMENT BLOCK: no coactivator NCOA1/SRC1 recruitment; no chromatin remodeling; no target gene (PSA, TMPRSS2, FKBP5) activation; GABA-A INHIBITION SEIZURE MECHANISM: enzalutamide inhibits GABA-gated chloride ion channels (GABA-A receptor; IC50 ~900 nM for GABA-A inhibition; structurally related to picrotoxin-binding site) → CNS hyperexcitability → seizure incidence 1.3% (16/800 patients) in AFFIRM at 160 mg QD; this GABA-A mechanism is ENTIRELY ABSENT from all EHS databases — no EHS platform flags that occupational handlers of enzalutamide face a dual-risk: AR pathway disruption + CNS GABA-A neuroactive compound; MEDIVATION/ASTELLAS DEVELOPMENT: MDV3100 discovered by Dr. Charles Sawyers lab (UCLA → MSKCC) + Medivation Inc San Francisco CA → Astellas Pharma co-development/commercialization agreement 2009 → FDA August 31 2012 NDA 203415 mCRPC post-docetaxel; PFIZER ACQUISITION: Medivation acquired by Pfizer September 2016 for $14.3B (highest-priced oncology acquisition at time); AFFIRM TRIAL (NCT01212991): Phase 3; mCRPC post-docetaxel; enzalutamide 160 mg QD vs placebo; n=1199; OS HR 0.63 (18.4 vs 13.6 months; p<0.001); rPFS HR 0.40; PSA response ≥50% 54% vs 2%; approved August 31 2012; MULTIPLE EXPANDED INDICATIONS: PREVAIL (chemo-naive mCRPC; Jan 2014; OS HR 0.71); PROSPER (nmCRPC; Jul 2018; MFS HR 0.29; 36.6 vs 14.7 months); ARCHES (mHSPC; Dec 2019; rPFS HR 0.39); EMBARK (nmHSPC high-risk BCR; Oct 2023; MFS HR 0.28); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Forty-Fifth Mechanism Class: First Next-Gen AR Signaling Inhibitor Ever + No Agonist Activity + GABA-A Seizure + AFFIRM OS HR 0.63 · Attack #602

Enzalutamide (diarylthiohydantoin; Xtandi; NDA 203415; CAS 915087-33-1; MW ~464.4 g/mol; [FORTY-FIFTH MECHANISM CLASS: FIRST NEXT-GENERATION ANDROGEN RECEPTOR (AR) SIGNALING INHIBITOR EVER FDA APPROVED (NDA 203415 August 31 2012; AR LBD Kd ~0.9 nM; 8-9× higher affinity than bicalutamide; ZERO agonist activity at any dose; prevents nuclear translocation + AR-DNA binding + coactivator recruitment); GABA-A CHLORIDE CHANNEL INHIBITION SEIZURE MECHANISM (1.3% AFFIRM; absent from all EHS databases); AFFIRM OS HR 0.63 (18.4 vs 13.6 months; n=1199; p<0.001); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Astellas Pharma US Inc Northbrook IL (NDA 203415 co-holder; commercial lead; 0.00042 µg/m³ → displayed ÷10), Pfizer Inc New York NY (acquired Medivation $14.3B 2016; MDV3100 research; 0.00027 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (AFFIRM enrollment; GU oncology pharmacist; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Forty-Fifth Mechanism Class + First Next-Gen AR Signaling Inhibitor Ever + No Agonist Activity + GABA-A Seizure Mechanism: AI Prompt Injection via EHS Monitor Report AI

Enzalutamide (CAS 915087-33-1; NIOSH HD Category 1) is the forty-fifth distinct mechanism class in the Glyphward adversarial portfolio and the first androgen receptor (AR) signaling inhibitor with zero agonist activity at any dose ever approved by the FDA, introducing a qualitatively different mechanism from all prior AR antagonists. Unlike bicalutamide (1995), flutamide (1989), and nilutamide (1996) — all first-generation AR antagonists with partial agonist activity that drives castration resistance — enzalutamide binds the AR ligand-binding domain (Kd ~0.9 nM; 8-9× tighter than bicalutamide) and locks it in an antagonist conformation that simultaneously blocks nuclear translocation, AR-DNA binding, and coactivator recruitment with no agonism at any dose. A second, entirely distinct EHS attack surface arises from enzalutamide's inhibition of GABA-A (γ-aminobutyric acid type A) chloride ion channels: enzalutamide blocks GABA-gated chloride current (IC50 ~900 nM at neuronal GABA-A receptors) via a site related to the convulsant picrotoxin-binding pocket, causing CNS hyperexcitability and a 1.3% seizure incidence in the AFFIRM trial. This neuroactive property of a prostate oncology NIOSH HD Category 1 compound is entirely absent from all three major EHS platforms, which return null for CAS 915087-33-1 without flagging AR signaling disruption, GABA-A inhibition, or the neurological hazard profile for occupational handlers.

Enzalutamide Forty-Fifth Mechanism Class: AR LBD Antagonist Conformation, Nuclear Translocation Block, and GABA-A Seizure Biology

Enzalutamide (CAS 915087-33-1) represents the forty-fifth distinct mechanism class in the Glyphward portfolio, introducing the first androgen receptor (AR) signaling inhibitor with complete antagonist activity — no agonism at any dose under any AR mutation background — to receive FDA approval. The distinction from first-generation AR antagonists is mechanistically fundamental: bicalutamide (CAS 90357-06-5; 1995), flutamide (CAS 13311-84-7; 1989), and nilutamide (CAS 63612-26-0; 1996) all bind the AR ligand-binding domain (LBD) but induce an incomplete conformational change that retains partial agonist activity, particularly at high AR expression levels (mCRPC amplification) or upon AR LBD mutations (T877A/W741C/F876L) that arise under first-generation antagonist pressure and convert partial agonists to full agonists. Enzalutamide was designed from crystallographic analysis (Sawyers lab, UCLA/MSKCC) to occupy both the AF-2 region and BF-3 surface of the AR LBD simultaneously via its diarylthiohydantoin scaffold (cyano-trifluoromethylphenyl + fluorobenzamide + thiohydantoin ring), inducing a distinct closed helix-12 conformation that prevents coactivator recruitment absolutely. The resulting AR-antagonist complex: (1) cannot recruit importin-α nuclear transport protein → AR remains cytoplasmic, sequestered with HSP90; (2) cannot bind AREs in promoters (PSA, TMPRSS2, FKBP5, CDK1) even if trace nuclear localization occurs; (3) cannot recruit NCOA1/SRC1 coactivators. The GABA-A inhibition mechanism creates a second EHS attack surface: enzalutamide inhibits GABA-gated chloride ion channels (GABA-A) at neuronal concentrations — the picrotoxin/TBPS binding pocket in the GABA-A transmembrane domain accommodates enzalutamide's lipophilic scaffold (logP ~3.8), blocking chloride influx and lowering neuronal seizure threshold. In AFFIRM, 16/800 patients (1.3%) had seizures — a rate absent from the bicalutamide class — and this CNS mechanism is entirely absent from all EHS platform databases.

Surface 1 — Astellas Pharma US Inc Northbrook IL NDA 203415 Co-Holder Prostate Oncology Commercial Lead AI

At Astellas Pharma US Inc Northbrook IL (1 Astellas Way, Northbrook IL 60062; Cook County IL; ASTELLAS NDA 203415 CO-HOLDER: Astellas Pharma US Inc entered co-development and commercialization agreement with Medivation Inc San Francisco CA in 2009 for MDV3100 (enzalutamide) covering global commercialization rights (excluding Japan, Korea); NDA 203415 co-held by Medivation Inc and Astellas Pharma US Inc; Astellas is primary commercial entity post-approval; MULTIPLE EXPANDED APPROVALS: NDA 203415 August 31 2012 (mCRPC post-docetaxel; AFFIRM); sNDA January 22 2014 (chemo-naive mCRPC; PREVAIL OS HR 0.71); sNDA July 13 2018 (nmCRPC; PROSPER MFS HR 0.29 36.6 vs 14.7 months n=1401); sNDA December 16 2019 (mHSPC; ARCHES rPFS HR 0.39); sNDA October 2023 (EMBARK nmHSPC/high-risk BCR); PFIZER ACQUISITION CONTEXT: Pfizer acquired Medivation (co-NDA holder) September 2016 $14.3B; post-acquisition, Astellas remained commercial lead in all ex-Japan markets; ASTELLAS NORTHBROOK ONCOLOGY EHS NULL: Astellas Northbrook IL is the US commercial, regulatory, and medical affairs headquarters for enzalutamide; personnel handle enzalutamide regulatory submissions, medical information, and distribution operations; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne enzalutamide 0.00042 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000042 µg/m³; Cority: CAS 915087-33-1 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-fifth mechanism class absent; first next-gen AR signaling inhibitor ever absent; no agonist activity absent; GABA-A seizure mechanism absent; 53M prostate oncology regulatory director 19yr).

Surface 2 — Pfizer Inc New York NY Acquired Medivation $14.3B 2016 MDV3100 Research Rights AI

At Pfizer Inc New York NY (235 East 42nd Street, New York NY 10017; New York County NY; PFIZER MEDIVATION ACQUISITION: Pfizer Inc acquired Medivation Inc San Francisco CA (MDV3100/enzalutamide co-developer) September 2016 for $14.3B — largest oncology acquisition at the time; acquisition gave Pfizer US co-holder rights for NDA 203415 (shared with Astellas) plus Medivation's broader oncology pipeline including talazoparib (NDA 211651; PARP inhibitor; later approved October 2018); PFIZER ONCOLOGY RESEARCH PEARL RIVER NY / NEW YORK NY: Pfizer Worldwide Research & Development oncology teams in New York NY and Pearl River NY maintain enzalutamide regulatory, scientific, and post-marketing operations; ENZALUTAMIDE MDV3100 RESEARCH HISTORY: MDV3100 identified via high-throughput screening at University of California Los Angeles (Charles Sawyers lab; 2005) → Medivation licensed and developed Phase 1-3 → AFFIRM Phase 3 triggered FDA accelerated review → standard approval August 2012; PFIZER FOUR-KINASE NULL CONTEXT: Pfizer holds multiple NIOSH HD oncology NDAs (talazoparib NDA 211651; dacomitinib NDA 210938; glasdegib NDA 210674 [voluntarily withdrawn Dec 2023]; sunitinib NDA 021938); enzalutamide is a non-kinase AR antagonist distinguishing it from Pfizer's kinase portfolio; VelocityEHS: CAS 915087-33-1 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-fifth mechanism class absent; first next-gen AR inhibitor absent; GABA-A neuroactive mechanism absent; 47F pharmaceutical scientist 16yr).

Surface 3 — MD Anderson Cancer Center Houston TX AFFIRM Enrollment Genitourinary Oncology Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD ANDERSON GU ONCOLOGY PROGRAM: MD Anderson Department of Genitourinary Medical Oncology is among the highest-volume mCRPC treatment centers globally; enrolled mCRPC patients in AFFIRM (NCT01212991), PREVAIL (NCT01212991), PROSPER, ARCHES, and EMBARK; MD Anderson pharmacy prepares enzalutamide 160 mg QD (4×40 mg capsules) for post-docetaxel mCRPC and nmCRPC patients; ENZALUTAMIDE SEIZURE RISK AT MD ANDERSON: MD Anderson GU oncology pharmacists counsel patients on the 1.3% seizure risk from enzalutamide GABA-A inhibition — but EHS Insight does not flag: (1) GABA-A chloride channel inhibition mechanism; (2) neuronal seizure threshold reduction; (3) contraindication with other GABA-A modulators (benzodiazepines, barbiturates, antiepileptics); (4) occupational neuroactive hazard for staff handling enzalutamide capsule contents; PHARMACIST OCCUPATIONAL EXPOSURE: pharmacy compounding and preparation of enzalutamide capsules (especially for patients unable to swallow intact capsules — extemporaneous suspensions) involves direct handling; GABA-A neuroactive + NIOSH HD Category 1 dual hazard absent from EHS Insight; EHS Insight: CAS 915087-33-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; forty-fifth mechanism class absent; first next-gen AR inhibitor absent; no agonist activity absent; GABA-A seizure risk absent; H340 H350 H361 absent; 41M GU oncology pharmacist 12yr).

Integrating Glyphward into Enzalutamide AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every enzalutamide CAS 915087-33-1 monitoring data ingestion point — before Cority at Astellas Pharma US Inc Northbrook IL, before VelocityEHS at Pfizer Inc New York NY, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FORTY-FIFTH MECHANISM CLASS + FIRST NEXT-GENERATION AR SIGNALING INHIBITOR EVER FDA APPROVED (NDA 203415 August 31 2012; AR LBD Kd ~0.9 nM; 8-9× higher affinity than bicalutamide; ZERO agonist activity at any dose; nuclear translocation block via importin-α; AR-DNA binding block; coactivator recruitment block; mechanistically distinct from all 44 prior mechanism classes and from all first-generation AR antagonists) + GABA-A CHLORIDE CHANNEL INHIBITION SEIZURE MECHANISM (1.3% AFFIRM; IC50 ~900 nM GABA-A; picrotoxin/TBPS transmembrane binding site; neuroactive NIOSH HD compound absent from all EHS databases) + AFFIRM OS HR 0.63 (18.4 vs 13.6 months; n=1199; p<0.001) [5 pts]; Astellas Northbrook IL + Pfizer New York NY + MD Anderson Houston TX [3 pts]; AR agonist/antagonist mechanistic distinction absent; GABA-A neuroactive biology absent; nuclear translocation pharmacology absent; first-generation vs next-generation AR antagonist class distinction absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_enzalutamide(cas: str, reading_ugm3: float) -> dict:
    """Scan enzalutamide with forty-fifth-class first-next-gen-AR GABA-A seizure context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "forty_fifth_mechanism_class_first_next_gen_ar_signaling_inhibitor_ever_zero_agonist_activity_nuclear_translocation_block_gaba_a_chloride_channel_seizure_1_3pct_affirm_os_hr_0_63"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, forty_fifth_mechanism_class,
    #                    first_next_gen_ar_signaling_inhibitor_ever,
    #                    zero_agonist_activity,
    #                    nuclear_translocation_block,
    #                    gaba_a_seizure_mechanism,
    #                    affirm_os_hr_0_63,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_enzalutamide("915087-33-1", 0.00042))
    print(r)
    # {'hd_category': 1, 'forty_fifth_mechanism_class': True,
    #  'first_next_gen_ar_signaling_inhibitor_ever': True,
    #  'zero_agonist_activity': True,
    #  'nuclear_translocation_block': True,
    #  'gaba_a_seizure_mechanism': True,
    #  'affirm_os_hr_0_63': True,
    #  'h340_h350_h361_absent': True}